✨
AI Summary
- Pascal Touchon discusses Atara Biotherapeutics' allogeneic approval.
- Ebvallo's groundbreaking approval as the first allogeneic T-cell immunotherapy.
- Path to regulatory approval and commercialization plans for Ebvallo.
Guests on This Episode
PT
Pascal Touchon
1 podcast appearance